The paper discussed in today's episode: Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-containing Regimens for Drug-sensitive TB: 12-Week Results
According to the World Health Organization, of the roughly 10 million people who fall ill with TB annually, over 80% survive.
Unfortunately, as with long Covid, being cured of TB is not always the last hurdle and many people go on to struggle with post-TB lung disease.
Tiyese Jeranji asked local experts about this sometimes-neglected area of TB care.
June 03, 2019 09:00 AM Eastern Daylight Time SEONGNAM-SI, South Korea–(BUSINESS WIRE)–Qurient Co. Ltd. today announced positive results from the Phase 2a EBA (early […]
08 – 09 April 2019 Partners from Statens Serum Institut, Aeras Africa, Ospedale San Raffaele, South African Tuberculosis Vaccine Initiative, The Aurum Institute, TASK Applied Science, […]
By MARSHA LEITCH June 27, 2018 Schools from in and around Mitchell’s Plain visited the Mitchell’s Plain Health Centre in Eastridge, where they discussed teenage pregnancy, […]
By MARSHA LEITCH July 25, 2018 The City of Cape Town’s parks and recreation department hosted a three-week holiday programme for up to 400 children […]
Teamwork: Dr Rod Dawson (right) and his team of (from left) Thami Mlonyeni, Bernie Isaacs, Michelle Evreva, Dr Kim Narunsky, Gloria Vusani, Lizette Rooi, and Suraya […]
A new clinical trial by the UCT Lung Institute’s Centre for TB Research Innovation (CTBRI) is not only innovative in design and in its collaborative nature, […]